Inhibitors of fatty acid synthesis as antimicrobial chemotherapeutics.
about
The evolution, metabolism and functions of the apicoplastStructure of 3-oxoacyl-(acyl-carrier protein) synthase II fromThermus thermophilusHB8Inhibition of the fungal fatty acid synthase type I multienzyme complexCrystal structures of bacterial FabH suggest a molecular basis for the substrate specificity of the enzymeMode of Action, In Vitro Activity, and In Vivo Efficacy of AFN-1252, a Selective Antistaphylococcal FabI InhibitorTowards a new tuberculosis drug: pyridomycin - nature's isoniazidUsing modern tools to probe the structure-function relationship of fatty acid synthasesA novel prokaryotic trans-2-enoyl-CoA reductase from the spirochete Treponema denticolaSignature gene expression profiles discriminate between isoniazid-, thiolactomycin-, and triclosan-treated Mycobacterium tuberculosisTriclosan resistance of Pseudomonas aeruginosa PAO1 is due to FabV, a triclosan-resistant enoyl-acyl carrier protein reductaseFatty acid biosynthesis in Pseudomonas aeruginosa is initiated by the FabY class of β-ketoacyl acyl carrier protein synthasesChemical interference of pathogen-associated molecular pattern-triggered immune responses in Arabidopsis reveals a potential role for fatty-acid synthase type II complex-derived lipid signals.Mass spectrometry-based systems approach for identification of inhibitors of Plasmodium falciparum fatty acid synthaseTargeting the fatty acid biosynthesis enzyme, beta-ketoacyl-acyl carrier protein synthase III (PfKASIII), in the identification of novel antimalarial agents.Identification and characterization of inhibitors of bacterial enoyl-acyl carrier protein reductaseStructure-based inhibitor design of AccD5, an essential acyl-CoA carboxylase carboxyltransferase domain of Mycobacterium tuberculosisPotential impact of increased use of biocides in consumer products on prevalence of antibiotic resistanceThe MUT056399 inhibitor of FabI is a new antistaphylococcal compound.Discovery of novel bacterial elongation condensing enzyme inhibitors by virtual screening.Mutations upstream of fabI in triclosan resistant Staphylococcus aureus strains are associated with elevated fabI gene expression.Comparative cell wall core biosynthesis in the mycolated pathogens, Mycobacterium tuberculosis and Corynebacterium diphtheriae.Only one of the five Ralstonia solanacearum long-chain 3-ketoacyl-acyl carrier protein synthase homologues functions in fatty acid synthesis.A Substrate Mimic Allows High-Throughput Assay of the FabA Protein and Consequently the Identification of a Novel Inhibitor of Pseudomonas aeruginosa FabA'FAS't inhibition of malaria.The plastid-derived organelle of protozoan human parasites as a target of established and emerging drugs.Fatty acids regulate stress resistance and virulence factor production for Listeria monocytogenes.Regulation of cell size in response to nutrient availability by fatty acid biosynthesis in Escherichia coli.The Francisella tularensis FabI enoyl-acyl carrier protein reductase gene is essential to bacterial viability and is expressed during infection.Application of functional genomics to pathway optimization for increased isoprenoid production.Novel acyl phosphate mimics that target PlsY, an essential acyltransferase in gram-positive bacteria.Gemfibrozil inhibits Legionella pneumophila and Mycobacterium tuberculosis enoyl coenzyme A reductases and blocks intracellular growth of these bacteria in macrophagesRecent advances in the chemistry and biology of naturally occurring antibiotics.Substituted diphenyl ethers as a broad-spectrum platform for the development of chemotherapeutics for the treatment of tularaemiaThe Burkholderia pseudomallei enoyl-acyl carrier protein reductase FabI1 is essential for in vivo growth and is the target of a novel chemotherapeutic with efficacy.New drug-targeting strategy from beneath the shell of egg.Crystallization and preliminary X-ray crystallographic studies of enoyl-acyl carrier protein reductase (FabI) from Psuedomonas aeruginosa.Bacterial fatty acid metabolism in modern antibiotic discovery.Activity of Debio1452, a FabI inhibitor with potent activity against Staphylococcus aureus and coagulase-negative Staphylococcus spp., including multidrug-resistant strains.Triclosan as a systemic antibacterial agent in a mouse model of acute bacterial challenge.In vitro inhibition of the Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein reductase MabA by isoniazid.
P2860
Q24652914-221DFC71-605F-474A-9354-9EED99A5EAEAQ27650519-C0611CD7-CCD9-4491-85A1-A6CA82CFDC5CQ27651798-888529B7-11C5-4BC5-99F9-20B4A91F690BQ27656925-2350C6EB-7CE4-4599-B05D-475DF379DDEFQ27671875-977C2FC8-C381-4F58-A997-C579BD815C28Q27673316-843B0426-5523-4DC8-92FD-DED7C94D5AE9Q28080940-4DDA72DF-2B25-4274-A6C8-C13F76B31B89Q28485601-6547864C-B7C4-4657-AAA6-1F4173DC20D6Q28487562-9940988A-1B1F-45E5-989A-8F88D6AB2942Q28492833-46882052-5076-41A3-9552-A1ACB3D16CC5Q28493145-65AB6846-777A-4BD5-A33F-178D66AFBC04Q33266497-B2E5CBC7-FF03-41F8-859C-E88F6DFF0459Q33283922-00704773-D000-4384-8911-1B7C096E0B64Q33605124-AF112BE8-01EC-4D38-A302-1985BBB62A09Q34315832-9F466142-0FD1-4DFD-BBDD-25BB14624CC3Q34480164-01127735-5085-422E-BF08-F22DEC73AD87Q34927172-B39AF464-6921-4F5B-B1C1-1D5AA96468F7Q35270339-402BEE94-B973-48D9-B20D-744AD4103DADQ35586118-CF628EC0-9A10-4E19-B57B-6E72E46607A2Q35618052-584ED353-FDC1-46F3-B88F-DBAED5F27E55Q35756648-72AC1968-5B5D-4F39-880D-151BAC2A4915Q35804851-4F6D5A48-E6B7-4CAB-8BE5-E8DB943C2526Q35839906-F8E34C1C-2FC5-4369-B47F-1288B9F9E015Q35865145-06CBEC0B-2C8D-42AA-9B2A-3D919C006688Q36066272-58011E16-3749-4AD1-B792-D6E7F7526785Q36276434-C7B90CF8-48D6-482D-A452-9BB3A7842C0AQ36280073-9091E929-6D7E-4041-B54E-EA12F10AC573Q36558861-E92626C1-565E-4E79-A84D-111103AE3409Q36672684-44C8F48A-FF4A-4C02-B7CF-AB1F9C385618Q37292453-C5CFEF73-50BC-451F-BAB2-41693203403EQ37302019-4E2B38E5-6AE3-4E2D-B80A-F7B9BF884768Q37313939-12FCF0FE-17A4-4CDD-A362-67BFF0A15B31Q37383936-E888D877-AC89-44B1-88E5-30BD05BB9074Q37544698-39E56268-35F0-4EC5-BCA4-3D6C9ED67281Q37788223-F5B524A4-75AB-4A26-AB52-3A4FB7FFA91BQ38477356-20864B4F-4E70-4354-9D66-89AC14D3F13EQ38964523-F90D2873-D417-4CCE-A25A-AA2AD5EB3052Q39565510-E6F0BF07-257E-4EEF-A4D6-ED4C281A17BDQ40345423-97F9CFEB-131F-4DB7-A307-8655E547074FQ40410540-9E1EAB5A-F39F-45FA-9585-6B88A3CEEF9A
P2860
Inhibitors of fatty acid synthesis as antimicrobial chemotherapeutics.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
Inhibitors of fatty acid synthesis as antimicrobial chemotherapeutics.
@ast
Inhibitors of fatty acid synthesis as antimicrobial chemotherapeutics.
@en
Inhibitors of fatty acid synthesis as antimicrobial chemotherapeutics.
@nl
type
label
Inhibitors of fatty acid synthesis as antimicrobial chemotherapeutics.
@ast
Inhibitors of fatty acid synthesis as antimicrobial chemotherapeutics.
@en
Inhibitors of fatty acid synthesis as antimicrobial chemotherapeutics.
@nl
prefLabel
Inhibitors of fatty acid synthesis as antimicrobial chemotherapeutics.
@ast
Inhibitors of fatty acid synthesis as antimicrobial chemotherapeutics.
@en
Inhibitors of fatty acid synthesis as antimicrobial chemotherapeutics.
@nl
P2093
P1476
Inhibitors of fatty acid synthesis as antimicrobial chemotherapeutics.
@en
P2093
P2888
P304
P356
10.1007/S00253-001-0918-Z
P407
P577
2002-03-07T00:00:00Z
P6179
1030687640